# Windward Bio

> Nasdaq-listed Swiss clinical-stage biotechnology company developing long-acting immunology drugs for asthma, COPD and skin disease.

## Why it is interesting

WWB began Nasdaq trading November 13 after a $175M gross IPO pricing. Its separate $50M Sanofi placement was conditional on closing. Two earlier private financings sum to $365M, not $365M of new IPO capital.

## Profile

- **Latest funding:** Crossover financing — $165M (May 4, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $365M
- **Stage:** public
- **Status:** public
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-15
- **Latest funding investors:** OrbiMed, RA Capital Management, Sanofi Ventures

## Key facts

- Issuer priced ~ $175M gross Nasdaq IPO, separate from conditional $50M Sanofi placement; legal closing expected Nov 16, 2026.
- $200M Series A announced Jan 2025, legally closed in $75M and $125M tranches according to SEC.
- $165M May 2026 crossover financing led by OrbiMed; cumulative historical private financing $365M.
- Clinical efficacy beyond interim Phase 2 biomarkers, approval and eventual pricing remain unproven.

## Funding history

- Crossover financing · $165M · May 4, 2026
  Source: https://www.globenewswire.com/news-release/2026/05/04/3286605/0/en/windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential.html
- $200M Series A (two actual tranches Jan 23 and Jul 11) · $200M · January 10, 2025
  Source: https://www.globenewswire.com/news-release/2025/01/10/3007703/0/en/Windward-Bio-Launches-With-200-Million-Series-A-Financing-to-Develop-Phase-2-Ready-Long-Acting-Anti-TSLP-Antibody-With-Best-in-Class-Potential-in-Asthma-and-COPD.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/windward-bio